(RTTNews) - MiNK Therapeutics (INKT), a clinical-stage company, said new translational data supporting the role of invariant natural killer T or iNKT cells in idiopathic pulmonary fibrosis or IPF were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results